Borosil Scientific Q2 FY27 Results Due October 28

Board meeting scheduled for October 28

Borosil Scientific Limited has announced that its board will meet on October 28, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. The results will cover both standalone and consolidated financial statements. The announcement, dated October 21, identifies the meeting as the company’s Q2 and first-half FY27 results approval meeting. Investors will look to the filing for the company’s reported financial performance during the September quarter. The disclosed information does not include revenue, profit, margin, or volume guidance. It also does not provide an earnings outlook ahead of the board meeting.

What the company will disclose

The planned disclosure concerns unaudited results for the three months ended September 30, 2026, along with the six-month period ended on the same date. Standalone results will reflect the company’s own financial performance, while consolidated results will include the relevant group-level position. The company has specifically stated that the board will approve both sets of results. Financial results and related materials are listed by the company under its Annual Reports and Financial Documents section. That section also carries quarterly results, earnings-call transcripts, and investor presentations. The October 28 outcome will therefore be the next formal financial update identified in the supplied disclosures.

Trading window closure noted in filings

The company’s announcements state that its trading window closed from October 1, 2026. It will remain closed until 48 hours after the Q2 results are announced. Such a closure is intended to restrict trading by designated persons during the period surrounding the preparation and release of unpublished price-sensitive information. The disclosure refers to the trading-window closure in connection with Q2 FY26, although the board meeting notice identifies the September 2026 quarter and half year as FY27 results. The supplied material does not explain this year-label difference. The confirmed point for investors is that the window was scheduled to remain closed through 48 hours after the results announcement.

Borosil Scientific’s operating profile

Borosil Scientific manufactures and sells laboratory glassware. Its portfolio includes laboratory glassware and consumables such as filtration products and analytical vials. The company also offers laboratory instrumentation used in nutrition and environment applications, lab essentials, life sciences, and liquid handling. Its pharma primary packaging range includes glass ampoules and tubular glass vials. In addition, it supplies laboratory process systems, including mini reactors, jacketed reactors, parallel reaction systems, automated reaction systems, photo and specialty systems, utilities, and accessories.

Product categories and manufacturing base

The company’s listed laboratory glassware range includes volumetric glassware, reagent bottles, beakers, test tubes, and petri dishes. Its laboratory glassware and consumables manufacturing facility is located at Bharuch, Gujarat. The facility covers 86,000 square feet, according to the supplied company information. Borosil Scientific also provides industrial process equipment and original equipment manufacturing solutions. This mix places the company across laboratory consumables, scientific equipment, pharmaceutical packaging, and process-system requirements. The upcoming results will be the formal source for financial information on these activities for the September 2026 quarter.

Recent corporate disclosures

The supplied filings also refer to a change in management involving the cessation of a senior management personnel member with effect from September 23, 2026. Another announcement is identified as a capacity-addition disclosure under Regulation 30 of the Listing Obligations and Disclosure Requirements regulations. The material does not provide further details of that capacity addition. A separate Regulation 30 disclosure refers to shifting factory operations from Tarapur to Bharuch. The provided information also mentions the demerger of Borosil Scientific Ltd. These disclosures form part of the company’s broader corporate-announcement record but do not alter the stated agenda for the October 28 board meeting.

Capacity references in supplied materials

The supplied materials include references to a 25-tonnes-per-day borosilicate glassware furnace commissioned in March 2024. They also refer to an expansion of a borosilicate glass furnace at Jaipur from 25 tonnes per day to 32 tonnes per day, with a third forming line. The cited estimated capital expenditure for that expansion is ₹50 crore, and the stated capacity utilisation is about 90%. The materials say the furnace was commissioned in January 2024 and that its rebuild is scheduled for January 2028. These capacity references appear in Borosil Limited’s Q2 FY26 investor presentation included in the supplied data and should not be treated as a financial result or forecast for Borosil Scientific’s upcoming Q2 FY27 filing.

Other manufacturing investment information

The supplied information also refers to a proposed manufacturing unit in Rajasthan for vacuum-insulated stainless-steel flasks, bottles, and containers. The planned facility would have three double-wall lines, estimated initial capital expenditure of ₹65 crore, and initial annual capacity of about 3.6 million units. Commercial production from two lines was targeted by the end of Q4 FY2026, with production from the third line targeted by the end of Q1 FY2027, subject to necessary approvals. These references provide context on manufacturing investment described in the materials. They do not constitute a confirmed Borosil Scientific financial contribution for the September 2026 quarter.

Key details at a glance

Why the announcement matters

The October 28 meeting is important because it will provide the company’s next reported financial position after the June 2026 quarter results listed in its financial-documents archive. The disclosure will give investors access to the unaudited quarterly and half-year numbers rather than estimates or preliminary commentary. It will also place recent corporate developments, including the factory-operations shift disclosure and management change, alongside updated reported figures. For the laboratory-products business, the results will be relevant to stakeholders tracking glassware, consumables, instrumentation, pharma packaging, and process-system operations. No share-price movement, analyst forecast, or financial estimate has been provided in the supplied material.

What to watch after the meeting

Borosil Scientific is scheduled to consider the September 2026 quarter and half-year results on October 28, 2026. Following approval, the company is expected to release the unaudited standalone and consolidated results in line with the board-meeting agenda. Investors can also monitor the company’s financial-documents section for quarterly results, presentations, and earnings-call materials where available. The trading window is stated to reopen 48 hours after the results announcement. Until the filing is released, the disclosed information confirms the reporting date and scope, but not the quarter’s financial outcome.